Avails Medical Awarded $2.5M in CARB-X Funding for the Development of its Rapid Antibiotic Susceptibility Testing Device to Identify the Most Effective Antibiotic Therapy
MENLO PARK, Calif., Feb. 1, 2021 /PRNewswire/ — Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today it was awarded up to $2.5M in non-dilutive funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. CARB-X is a global non-profit partnership based at Boston University School of Law and dedicated to funding the development of new antibiotics, vaccines, diagnostics and other products to address antibiotic-resistant bacteria.
Funds will support the development of Avails Medicals’ eAST technology, a fully electrical antibiotic susceptibility testing (AST) device to significantly reduce the time-to-results and enable health care providers to rapidly determine the most effective antibiotic treatment for patients with severe bloodstream infections, especially those involving multidrug-resistant pathogens.